Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05275205 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)
A Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Unity Biotechnology.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 14
- Study locations
NCT05275205: Completed Phase 2 study of Neovascular Age-related Macular Degeneration, sponsored by Unity Biotechnology.
NCT05275205 is a Phase 2 study of Neovascular Age-related Macular Degeneration that has completed, run by Unity Biotechnology. The registered enrollment target is 51 participants, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (87% lower). The trial reports 14 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05275205, a Phase 2 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Unity Biotechnology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 14
- Study locations
Study Summary
This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
Primary Outcome
Ocular and systemic safety and tolerability of a repeat IVT injection of UBX1325 compared to active-control (aflibercept) evaluated by treatment emergent adverse events (TEAEs) through Week 24
Conditions Studied
Interventions
- DRUG UBX1325 injection 50 μL
- DRUG EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Study Locations (14)
Texas
- Retina Research Institution of Texas - Abilene
- Valley Retina Institute - McAllen
- Austin Retina Associates - Round Rock
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- Salehi Retina Institute - Huntington Beach
Florida
- Rand Eye Institute - Deerfield Beach
- Retina Vitreous Associates of Florida - St. Petersburg
Illinois
- University Retina and Macula Associates - Lemont
- Illinois Eye Center - Peoria
Colorado
- Advanced Vision Research Institute - Longmont
Indiana
- Midwest Eye - Carmel
Minnesota
- Mayo Clinic-Rochester - Rochester
Nevada
- Sierra Eye Associates - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2022-03-02 |
| Est. Completion | 2023-07-25 |
| Phase | Phase 2 |
What the finished NCT05275205 record still lists
NCT05275205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which UBX1325 injection 50 μL is the first listed.
NCT05275205 lists 14 locations in 9 states (Texas, California, Florida).
Frequently Asked Questions
What is clinical trial NCT05275205 about?
NCT05275205 is a clinical study titled "Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)". This study is intended to assess safety, tolerability and biological activity of a repeat IVT injection of UBX1325 in patients with wet AMD.
What is the current status of trial NCT05275205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2022-03-02. Estimated completion is 2023-07-25.
What conditions does trial NCT05275205 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT05275205?
The interventions under investigation include: UBX1325 injection 50 μL (DRUG), EYLEA® (aflibercept) Injection 2 mg (0.05mL) (DRUG).
Who is sponsoring clinical trial NCT05275205?
This trial is sponsored by Unity Biotechnology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05275205 being conducted?
This trial has 14 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05275205's enrollment target sits among peer trials
51 22nd of 33 higher than 12 of 33 other Neovascular Age-related Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neovascular Age-related Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD
COMPLETED · Phase 2
-
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
COMPLETED · Phase 2
-
Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI